Sleep Disorders

Here's what is coming soon to NeurologyLive.

William Noah, MD, director and founder of the Sleep Centers of Middle Tennessee discussed issues in caring for patients with OSA.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending April 23, 2021.

The director and founder of the Sleep Centers of Middle Tennessee discussed trends in positive airway pressure adherence that his center’s research has revealed.

Researchers saw the least amount of adverse events and the least time to stable dose in participants entering the study with SXB treatment.

The 2021 AAN Meeting Hot Topics plenary focused on neurological facets of COVID-19, and featured insight from Anthony Fauci, MD, of NIAID, and Walter Koroshetz, MD, of NINDS, among others.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending April 16, 2021.

The director and founder of the Sleep Centers of Middle Tennessee discussed strategies to achieve long term adherence to cPAP from patients with obstructive sleep apnea.

The 2021 AAN Annual Meeting will be held virtually from April 17-22. Follow along with coverage from NeurologyLive, including expert interviews and session recaps.

The director and founder of the Sleep Centers of Middle Tennessee discussed the OSAinHome program that his practice has developed.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending April 9, 2021.

The director and founder of the Sleep Centers of Middle Tennessee discussed his team’s efforts to further patient understanding of obstructive sleep apnea.

Expert neurologists discuss advancements in the management of narcolepsy including new drug formulations and provide take-home messages for how to improve diagnosis and treatment in the future.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending April 2, 2021.

The SINBAR EMG, percentage of RWA from mentalis tonic and any activity, and percentage of RWA from FDS phasic activity all correlated with both disease duration and levodopa-equivalent dose.

Researchers studied associations between obstructive sleep apnea and varied markers of adiposity.

If approved, daridorexant would become the first sleep medication to demonstrate an improvement in sleep and daytime functioning, while keeping a favorable safety profile in adult and elderly patients.

Researchers found that taking into account PWA increased total arousal index more than 3-fold.

Key opinion leaders consider the impact of the COVID-19 pandemic on the diagnosis and treatment of narcolepsy and comment on improvements in symptom management at home.

Experts in neurology review the recent approvals of pitolisant and solriamfetol for the management of excessive daytime sleepiness (EDS) and compare their mechanisms of action.

Here's what is coming soon to NeurologyLive.

The director and founder of the Sleep Centers of Middle Tennessee discussed the misleading nature of the term ‘sleep apnea.’

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending March 26, 2021.

Treatment adherence and preference were largely in favor of the mandibular advancement device compared to continuous positive airway pressure.

Key opinion leaders discuss pharmacotherapeutic options for the management of narcolepsy symptoms and examine the safety and efficacy of potential treatments.

Experts in neurology discuss the goals of treatment and consider behavioral approaches to the management of narcolepsy and idiopathic hypersomnia including naps and exposure to sunlight.

Here's what is coming soon to NeurologyLive.